Gardos pathway to sickle cell therapies?
Author:
- 15 April 2008
- journal article
- editorial
- Published by American Society of Hematology in Blood
- Vol. 111 (8) , 3918-3919
Abstract
In this issue of Blood, Ataga and colleagues report that treatment of sickle cell disease patients with senicapoc, a Gardos channel inhibitor, reduces the number of dehydrated cells, increases hemoglobin levels, and diminishes hemolysis.Keywords
This publication has 8 references indexed in Scilit:
- Deconstructing sickle cell disease: Reappraisal of the role of hemolysis in the development of clinical subphenotypesBlood Reviews, 2007
- Urea stimulation of KCl cotransport induces abnormal volume reduction in sickle reticulocytesBlood, 2006
- Dehydration response of sickle cells to sickling-induced Ca++ permeabilizationBlood, 2002
- Inhibition of Ca(2+)-dependent K+ transport and cell dehydration in sickle erythrocytes by clotrimazole and other imidazole derivatives.Journal of Clinical Investigation, 1993
- Sickle cell anemia with few painful crises is characterized by decreased red cell deformability and increased number of dense cellsAmerican Journal of Hematology, 1991
- The Irreversibly Sickled Cell; a Determinant of Haemolysis in Sickle Cell AnaemiaBritish Journal of Haematology, 1969
- The function of calcium in the potassium permeability of human erythrocytesBiochimica et Biophysica Acta, 1958
- POTASSIUM AND SODIUM OF RED BLOOD CELLS IN SICKLE CELL ANEMIA 1Journal of Clinical Investigation, 1952